Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 1688 results for carers

  1. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development [GID-TA10966] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

    In development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Iptacopan for treating complement 3 glomerulopathy ID6283

    In development [GID-TA11331] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Benefits of implementing NICE guidance

    NICE guidance on the benefits of implementing

  7. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Awaiting development [GID-TA11399] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development [GID-TA11198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]

    In development [GID-TA11495] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

    NICE guideline
    Last updated
    16 January 2023

    Sections for NG209